Hirudoid (Chondroitin Polysulfate)

Hirudoid is indicated for topical use in conditions where localized swelling, bruising, or superficial clot formation occurs, helping to manage the inflammatory response and support normal tissue recovery.

• Bruising (contusions) caused by blunt trauma, applied to reduce discoloration and swelling.
• Superficial thrombophlebitis affecting small veins, used to limit clot extension and inflammation.
• Hematoma formation after injury, applied to facilitate fluid resorption.
• Post‑traumatic swelling of muscles or soft tissue, helping to decrease edema.
• Minor edema associated with superficial burns or insect bites, supporting faster resolution.

• Chondroitin polysulfate is a heparinoid that interferes with the coagulation cascade and inflammatory pathways at the site of application. By binding to antithrombin III and inhibiting thrombin formation, it reduces fibrin deposition. Simultaneously, it limits leukocyte migration and the release of pro‑inflammatory mediators, resulting in decreased local edema and pain. The effect is confined to the skin and underlying tissues because systemic absorption is minimal.

Topical application of Hirudoid may be associated with local skin reactions; most are mild and reversible, while rare serious events have been reported.

Common

• Mild erythema or redness localized to the application area, usually resolving within 24–48 hours.
• Slight itching or pruritus that diminishes with continued use.
• Minor skin dryness or peeling that improves with moisturisation.
• Transient burning or stinging sensation on first use, typically subsiding after a few minutes.

Serious

• Allergic contact dermatitis with widespread redness, swelling, and vesicles that may need medical attention.
• Severe ulceration or necrosis of the skin at the site of application.
• Systemic hypersensitivity reactions such as urticaria or angio‑edema.
• Extension of swelling beyond the treated area indicating an adverse response.

When using Hirudoid, certain precautions should be observed to minimise the risk of adverse reactions and ensure safe application.

• Do not apply to broken skin, open wounds, or mucous membranes.
• Avoid use on areas with active infection or severe dermatitis.
• Perform a patch test on a small skin area before first use.
• Keep the product out of reach of children and store at room temperature away from direct sunlight.
• Discontinue use and seek medical advice if signs of allergic reaction appear.

Topical chondroitin polysulfate may interact with other agents applied to the skin or systemic medications that affect coagulation.

Avoid

• Concurrent use with other topical heparinoids or anticoagulant creams, which may increase local bleeding risk.
• Application over areas treated with strong irritants or chemical peels, which can exacerbate skin irritation.

Use with caution

• Systemic anticoagulants (e.g., warfarin, direct oral anticoagulants) – monitor for increased bleeding if large skin areas are treated.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) applied topically – assess for additive anti‑inflammatory effects.
• Corticosteroid creams – consider potential alteration of skin barrier function.